These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37335862)

  • 1. Comparison of effectiveness and safety of sodium polystyrene sulfonate and sodium zirconium cyclosilicate for treatment of hyperkalemia in hospitalized patients.
    Sullivan E; Ruegger M; Dunne I; Sutaria N; Towers WF
    Am J Health Syst Pharm; 2023 Sep; 80(18):1238-1246. PubMed ID: 37335862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single Dose of Sodium Zirconium Cyclosilicate Versus Sodium Polystyrene Sulfonate in Hospitalized Patients With Hyperkalemia.
    Yoo N; Song YB; Dubinsky I; Altshuler J
    Ann Pharmacother; 2023 Sep; 57(9):1044-1052. PubMed ID: 36637028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium polystyrene sulfonate versus sodium zirconium cyclosilicate for the treatment of hyperkalemia in the emergency department.
    Hasara S; Dubey J; Amatea J; Finnigan N
    Am J Emerg Med; 2023 Mar; 65():59-64. PubMed ID: 36586223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum potassium response to single-dose sodium zirconium cyclosilicate for the treatment of asymptomatic hyperkalemia in hospitalized patients.
    Lewis H; Stamper B; Yungkurth AC
    Pharmacotherapy; 2024 Jan; 44(1):13-21. PubMed ID: 37475499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Efficacy of Sodium Zirconium Cyclosilicate and Sodium Polystyrene Sulfonate for Acute Hyperkalemia: A Retrospective Chart Review.
    Gonzalez J; Nayyar D
    Hosp Pharm; 2024 Apr; 59(2):159-164. PubMed ID: 38450357
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of Sodium Zirconium Cyclosilicate to Sodium Polystyrene Sulfonate in the Inpatient Management of Acute Hyperkalemia.
    Joyce O; Corpman M
    J Pharm Pract; 2024 Jun; 37(3):728-735. PubMed ID: 37254518
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate.
    Oshima A; Imamura T; Narang N; Kinugawa K
    Clin Cardiol; 2021 Sep; 44(9):1272-1275. PubMed ID: 34263946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.
    Zhang Y; Xu R; Wang F; Liu Y; Xu J; Zhao N; Cheng F; Long L; Jia J; Lin S
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1057-1066. PubMed ID: 33459923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
    Takkar C; Nassar T; Qunibi W
    Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of different potassium-lowering regimens on acute hyperkalemia in hemodialysis patients: a real-world, retrospective study.
    Yao L; Xing X; Li Y; Zhang F; Li P; Liang X; Wang P
    J Transl Med; 2022 Jul; 20(1):333. PubMed ID: 35879718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study.
    Kashihara N; Nishio T; Osonoi T; Saka Y; Imasawa T; Ohtake T; Mizuno H; Shibagaki Y; Kim H; Yajima T; Sarai N
    Clin Exp Nephrol; 2020 Dec; 24(12):1144-1153. PubMed ID: 32779057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent.
    Rastogi A; Hanna RM; Mkrttchyan A; Khalid M; Yaqoob S; Shaffer K; Dhawan P; Nobakht N; Kamgar M; Goshtaseb R; Sarmosyan K; Gnarini M; Wassef O; Lerma E
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1055-1064. PubMed ID: 34227913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of sodium zirconium cyclosilicate for the management of acute and chronic hyperkalemia in children with chronic kidney disease 4-5 and on dialysis.
    Khandelwal P; Shah S; McAlister L; Cleghorn S; King L; Shroff R
    Pediatr Nephrol; 2024 Apr; 39(4):1213-1219. PubMed ID: 37857905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Patiromer Versus Sodium Zirconium Cyclosilicate for the Management of Acute Hyperkalemia.
    Rydell A; Thackrey C; Molki M; Mullins BP
    Ann Pharmacother; 2023 Nov; ():10600280231209968. PubMed ID: 37953506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
    Kosiborod M; Rasmussen HS; Lavin P; Qunibi WY; Spinowitz B; Packham D; Roger SD; Yang A; Lerma E; Singh B
    JAMA; 2014 Dec; 312(21):2223-33. PubMed ID: 25402495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
    Schaefer JA; Gales MA
    Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia.
    Dong L; Xu W; Deng Y; Tan J; Qin W
    Eur J Pharmacol; 2022 Sep; 931():175174. PubMed ID: 35964658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin-angiotensin-aldosterone system inhibitors: a retrospective observational study.
    Kimura W; Minatoguchi S; Mizuno T; Koide S; Hayashi H; Hasegawa M; Inaguma D; Tsuboi N
    J Nephrol; 2024 Jan; 37(1):171-179. PubMed ID: 37608241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potassium-lowering effects of sodium zirconium cyclosilicate in the early post-transplant period.
    Shockey W; Wiegel JJ; Parajuli S; Garg N; Swanson KJ; Mandelbrot DA
    Clin Transplant; 2024 Jan; 38(1):e15156. PubMed ID: 37812572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
    Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
    J Am Soc Nephrol; 2019 Sep; 30(9):1723-1733. PubMed ID: 31201218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.